Skip to main content
ArticleOPEN ACCESS

Zometa in the treatment of diseminated prostate cancer.

Acta chirurgica Iugoslavica
DOI: 10.2298/ACI0504119D
0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Zoledronic acid is the first bisphosphonat that confirms the a efficacy in the treatment of bone metastases in prostate carcinoma. That is the most potent bisphosphonat up to date which safe and simple administration. Zometa is strong inhibitor of osteoclast activity.

Cite

CITATION STYLE

APA

Djokic, M. (2005). Zometa in the treatment of diseminated prostate cancer. Acta Chirurgica Iugoslavica. https://doi.org/10.2298/ACI0504119D

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free